AzurRx's Stock Falls After MS1819 For Pancreatic Insufficiency Flunks Mid-Stage Study

Benzinga

2021-04-01

AzurRx BioPharma Inc (NASDAQ: AZRX) reported topline results from its Phase 2b OPTION 2 trial evaluating MS1819 in cystic fibrosis patients with exocrine pancreatic insufficiency.
MS1819 demonstrated to be safe and well-tolerated. However, the study did not consistently meet the primary efficacy endpoint.
Some patients achieved a coefficient of fat absorption (CFA) at levels beyond what is required to demonstrate non-inferiority with porcine enzyme replacement therapy (PERT) therapies, but the majority did not.
The company believes that the leading cause of the drug's uneven efficacy performance lies with the enteric capsule formulation.
While the enteric coating protects the capsule from breaking down in the stomach acid, it also appears to dissolve too slowly in the small intestine to release the lipase enzyme for proper digestion and nutrient absorption.
The company is planning to pursue a new formulation for MS1819, this one a capsule filled with acid-resistant granules, or microbeads, similar to what is used in CREON, ZENPEP, and other PERT therapies.
MS1819 is a recombinant lipase enzyme for treating exocrine pancreatic insufficiency associated with cystic fibrosis and chronic pancreatitis.
Price Action: AZRX shares dropped 23.9% at $0.988 in the premarket session on the last check Thursday.

See more from Benzinga

Click here for options trades from Benzinga
BioXcel Stock Is Trading Lower After BXCL501 Data In Opioid Withdrawal Study
15M Doses Of JNJ COVID-19 Vaccine Batch Ruined After Ingredient Issues At Emergent Biosolutions' US Plant: NYT

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2124078437"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2124078437\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2124078437?lang=zh_TW&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/3ftOn8OtTEOHyElVVNcvXQ--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/1_sYaPbArqkNgugGXGLzAg--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/b1cf0ab80b3e00627f755b0e39f386e6","is_english":true,"pubTime":"2021-04-01 18:30","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2124078437","market":"us","top_or_hot":-1,"title":"AzurRx's Stock Falls After MS1819 For Pancreatic Insufficiency Flunks Mid-Stage Study","media":"Benzinga","content":"<html><body><img height=\"400\" src=\"https://s1.yimg.com/uu/api/res/1.2/02AtcOsc2IU0_Ve.UrLY_g--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/Benzinga/b1cf0ab80b3e00627f755b0e39f386e6\" title=\"\" width=\"600\"/>\n<ul>\n<li><strong>AzurRx BioPharma Inc</strong> (NASDAQ: AZRX) reported topline results from its Phase 2b OPTION 2 trial evaluating MS1819 in cystic fibrosis patients with exocrine pancreatic insufficiency.</li>\n<li>MS1819 demonstrated to be safe and well-tolerated. However, the study did not consistently meet the primary efficacy endpoint.</li>\n<li>Some patients achieved a coefficient of fat absorption (CFA) at levels beyond what is required to demonstrate non-inferiority with porcine enzyme replacement therapy (PERT) therapies, but the majority did not.</li>\n<li>The company believes that the leading cause of the drug's uneven efficacy performance lies with the enteric capsule formulation.</li>\n<li>While the enteric coating protects the capsule from breaking down in the stomach acid, it also appears to dissolve too slowly in the small intestine to release the lipase enzyme for proper digestion and nutrient absorption.</li>\n<li>The company is planning to pursue a new formulation for MS1819, this <a href=\"https://laohu8.com/S/AONE\">one</a> a capsule filled with acid-resistant granules, or microbeads, similar to what is used in CREON, ZENPEP, and other PERT therapies.</li>\n<li>MS1819 is a recombinant lipase enzyme for treating exocrine pancreatic insufficiency associated with cystic fibrosis and chronic pancreatitis.</li>\n<li><strong>Price Action:</strong> AZRX shares dropped 23.9% at $0.988 in the premarket session on the last check Thursday.</li>\n</ul>\n<p><strong>See more from Benzinga</strong></p>\n<ul>\n<li>Click here for options trades from Benzinga</li>\n<li>BioXcel Stock Is Trading Lower After BXCL501 Data In Opioid Withdrawal Study</li>\n<li>15M Doses Of JNJ COVID-19 Vaccine Batch Ruined After Ingredient Issues At <a href=\"https://laohu8.com/S/EBS\">Emergent Biosolutions</a>' US Plant: NYT</li>\n</ul>\n<p><i>© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.</i></p></body></html>","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AzurRx's Stock Falls After MS1819 For Pancreatic Insufficiency Flunks Mid-Stage Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAzurRx's Stock Falls After MS1819 For Pancreatic Insufficiency Flunks Mid-Stage Study\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Benzinga</strong><span class=\"h-time small\">2021-04-01 18:30</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body><img height=\"400\" src=\"https://s1.yimg.com/uu/api/res/1.2/02AtcOsc2IU0_Ve.UrLY_g--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/Benzinga/b1cf0ab80b3e00627f755b0e39f386e6\" title=\"\" width=\"600\"/>\n<ul>\n<li><strong>AzurRx BioPharma Inc</strong> (NASDAQ: AZRX) reported topline results from its Phase 2b OPTION 2 trial evaluating MS1819 in cystic fibrosis patients with exocrine pancreatic insufficiency.</li>\n<li>MS1819 demonstrated to be safe and well-tolerated. However, the study did not consistently meet the primary efficacy endpoint.</li>\n<li>Some patients achieved a coefficient of fat absorption (CFA) at levels beyond what is required to demonstrate non-inferiority with porcine enzyme replacement therapy (PERT) therapies, but the majority did not.</li>\n<li>The company believes that the leading cause of the drug's uneven efficacy performance lies with the enteric capsule formulation.</li>\n<li>While the enteric coating protects the capsule from breaking down in the stomach acid, it also appears to dissolve too slowly in the small intestine to release the lipase enzyme for proper digestion and nutrient absorption.</li>\n<li>The company is planning to pursue a new formulation for MS1819, this <a href=\"https://laohu8.com/S/AONE\">one</a> a capsule filled with acid-resistant granules, or microbeads, similar to what is used in CREON, ZENPEP, and other PERT therapies.</li>\n<li>MS1819 is a recombinant lipase enzyme for treating exocrine pancreatic insufficiency associated with cystic fibrosis and chronic pancreatitis.</li>\n<li><strong>Price Action:</strong> AZRX shares dropped 23.9% at $0.988 in the premarket session on the last check Thursday.</li>\n</ul>\n<p><strong>See more from Benzinga</strong></p>\n<ul>\n<li>Click here for options trades from Benzinga</li>\n<li>BioXcel Stock Is Trading Lower After BXCL501 Data In Opioid Withdrawal Study</li>\n<li>15M Doses Of JNJ COVID-19 Vaccine Batch Ruined After Ingredient Issues At <a href=\"https://laohu8.com/S/EBS\">Emergent Biosolutions</a>' US Plant: NYT</li>\n</ul>\n<p><i>© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.</i></p></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://finance.yahoo.com/news/azurrxs-stock-falls-ms1819-pancreatic-103044978.html\">Benzinga</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://finance.yahoo.com/news/azurrxs-stock-falls-ms1819-pancreatic-103044978.html","article_id":"2124078437","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/3ftOn8OtTEOHyElVVNcvXQ--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/1_sYaPbArqkNgugGXGLzAg--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/b1cf0ab80b3e00627f755b0e39f386e6"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2124078437","pubTimestamp":1617273044,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"AzurRx BioPharma Inc (NASDAQ: AZRX) reported topline results from its Phase 2b OPTION 2 trial evalua","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"MS1819治疗胰腺功能不全的中期研究失败后Azurrx的股票下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZRX":0.9},"content_text":"AzurRx BioPharma Inc (NASDAQ: AZRX) reported topline results from its Phase 2b OPTION 2 trial evaluating MS1819 in cystic fibrosis patients with exocrine pancreatic insufficiency.\nMS1819 demonstrated to be safe and well-tolerated. However, the study did not consistently meet the primary efficacy endpoint.\nSome patients achieved a coefficient of fat absorption (CFA) at levels beyond what is required to demonstrate non-inferiority with porcine enzyme replacement therapy (PERT) therapies, but the majority did not.\nThe company believes that the leading cause of the drug's uneven efficacy performance lies with the enteric capsule formulation.\nWhile the enteric coating protects the capsule from breaking down in the stomach acid, it also appears to dissolve too slowly in the small intestine to release the lipase enzyme for proper digestion and nutrient absorption.\nThe company is planning to pursue a new formulation for MS1819, this one a capsule filled with acid-resistant granules, or microbeads, similar to what is used in CREON, ZENPEP, and other PERT therapies.\nMS1819 is a recombinant lipase enzyme for treating exocrine pancreatic insufficiency associated with cystic fibrosis and chronic pancreatitis.\nPrice Action: AZRX shares dropped 23.9% at $0.988 in the premarket session on the last check Thursday.\n\nSee more from Benzinga\n\nClick here for options trades from Benzinga\nBioXcel Stock Is Trading Lower After BXCL501 Data In Opioid Withdrawal Study\n15M Doses Of JNJ COVID-19 Vaccine Batch Ruined After Ingredient Issues At Emergent Biosolutions' US Plant: NYT\n\n© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}